Evidence map›Paper›PMID 29239081›Full record

ArticleChembiochem : a European journal of chemical biology2018

Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy.

John M Egner, Davin R Jensen, Michael D Olp, Nolan W Kennedy, Brian F Volkman, Francis C Peterson, Brian C Smith, R Blake Hill

Open access · greenAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

John M EgnerDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.ORCID 0000-0003-2572-1368
Davin R JensenDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Michael D OlpDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Nolan W KennedyDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Brian F VolkmanDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Francis C PetersonDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Brian C SmithDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
R Blake HillDepartment of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.ORCID 0000-0001-6228-3905
Medical College of Wisconsin · US

Funding

Clinical and Translational Science AwardUL1TR001436 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI FREED, JULIE K · 2015 to 2025
$47.5M
Structural Biology of Mitochondrial FissionR01GM067180 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI HILL, R BLAKE · 2004 to 2022
$6.0M
Medical Scientist Training ProgramT32GM080202 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, SALZMAN, NITA H · 2010 to 2024
$5.7M
Structural Basis for Chemokine FunctionR01AI058072 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2004 to 2019
$4.1M
Endothelial function in human diabetes: role of mitochondrial fission proteinsR01HL128240 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI WIDLANSKY, MICHAEL E · 2016 to 2020
$2.9M
Sulfotyrosine-guided discovery of small molecule chemokine inhibitorsR01GM097381 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2011 to 2021
$2.9M
MicroRNA-29b and Endothelial FunctionR01HL125409 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI LIANG, MINGYU, WIDLANSKY, MICHAEL E · 2015 to 2018
$2.0M
Targeting CCL28 as therapy for obstructive lung diseaseR01AI120655 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2015 to 2018
$1.5M
High Performance Digital Console and Sample JetS10OD020000 · OD · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2015 to 2015
$600k
American Heart Association-American Stroke Association 15SDG25830057NCATS NIH HHS UL1 TR001436NHLBI NIH HHS R01 HL125409NHLBI NIH HHS R01 HL128240NIAID NIH HHS R01 AI058072NIAID NIH HHS R01 AI120655NIGMS NIH HHS R01 GM067180NIGMS NIH HHS R01 GM097381NIGMS NIH HHS T32 GM080202NIH HHS S10 OD020000
6 · The paper itself

Abstract

An academic chemical screening approach was developed by using 2D protein-detected NMR, and a 352-chemical fragment library was screened against three different protein targets. The approach was optimized against two protein targets with known ligands: CXCL12 and BRD4. Principal component analysis reliably identified compounds that induced nonspecific NMR crosspeak broadening but did not unambiguously identify ligands with specific affinity (hits). For improved hit detection, a novel scoring metric-difference intensity analysis (DIA)-was devised that sums all positive and negative intensities from 2D difference spectra. Applying DIA quickly discriminated potential ligands from compounds inducing nonspecific NMR crosspeak broadening and other nonspecific effects. Subsequent NMR titrations validated chemotypes important for binding to CXCL12 and BRD4. A novel target, mitochondrial fission protein Fis1, was screened, and six hits were identified by using DIA. Screening these diverse protein targets identified quinones and catechols that induced nonspecific NMR crosspeak broadening, hampering NMR analyses, but are currently not computationally identified as pan-assay interference compounds. The results established a streamlined screening workflow that can easily be scaled and adapted as part of a larger screening pipeline to identify fragment hits and assess relative binding affinities in the range of 0.3-1.6 mm. DIA could prove useful in library screening and other applications in which NMR chemical shift perturbations are measured.

Indexed as

Bromodomain Containing ProteinsCell Cycle ProteinsChemokine CXCL12Drug DiscoveryHumansLigandsMembrane ProteinsMitochondrial ProteinsModels, MolecularNuclear Magnetic Resonance, BiomolecularNuclear ProteinsPrincipal Component AnalysisProtein BindingRecombinant ProteinsSmall Molecule LibrariesTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsChemokine CXCL12FIS1 protein, humanLigandsMembrane ProteinsMitochondrial ProteinsNuclear ProteinsRecombinant ProteinsSmall Molecule LibrariesTranscription Factorsdrug discoveryfragment-based screeningNMR spectroscopyPAINSprincipal component analysis

Identifiers

PMID29239081
PMCPMC5844354
OpenAlexW2773633818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.